bioAffinity Technologies (BIAF) announced that William Bauta, Ph.D., has been appointed Chief Science Officer. Before joining bioAffinity in 2016 as Senior Vice President of Research and Development, Dr. Bauta was the Associate Director of Science at Genzyme Corporation and held a similar position at Ilex Products, Inc., where he was responsible for the discovery, development and FDA approval of therapeutics in the companies’ pipelines, and Manager of Medicinal and Process Chemistry at Southwest Research Institute.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIAF:
- BioAffinity Technologies issued patent by Japan Patent Office
- BioAffinity Technologies announces closing of $2.6M registered direct offering
- BioAffinity Technologies announces pricing of $2.66M registered direct offering
- BioAffinity Technologies’ CyPath lung cancer test supported in publication
- bioAffinity Technologies Welcomes Back CFO for Future Growth